Document is current
Any future updates will be listed below
-
Authors
Hao, Xinyan
Tang, Yucheng
Xu, Wenjie
Wang, Ming
Liu, Jiayi
Li, Yongjiang
He, Jun
Peng, Yanjin
Sun, Pengcheng
Liao, Dehua
Hu, Xiongbin
Tang, Tiantian
Zhou, Min
Han, Ruyue
Wang, Jiemin
Conde, João
Xiang, Daxiong
Wu, Junyong
-
Funding
Funding for this research was provided by:
Natural Science Foundation of Hunan Province (2024JJ5480, 2023JJ60505, 2023JJ40860)
the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Program (ERC-StG-2019-848325)
National Natural Science Foundation of China (82373295, 82304424)
Health Commission of Hunan province, China (W20242009, W20243128)
Natural Science Foundation of Changsha, Hunan Province, China (kq2208346)
China Postdoctoral Science Foundation (2023M733962)
Postdoctoral Fellowship Program of CPSF (GZB20230873)
- License Information
-
More Information
Article History
Received: 5 September 2024
Accepted: 2 January 2025
First Online: 15 January 2025
Declarations
:
: All animal experiments were performed according to the protocols and reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the Second Xiangya Hospital, Central South University, China (20220623).
: J.C. is a co-founder and shareholder of TargTex S.A. – Targeted therapeutics for Glioblastoma Multiforme. J.C. is also a member of the Global Burden Disease (GBD) consortium of the Institute for Health Metrics and Evaluation (IHME), University of Washington (US) and is in the Scientific Advisory board of Vector Bioscience Cambridge. The other authors declare no conflict of interest.
